Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon Apr 26, 2021 11:24pm
229 Views
Post# 33072405

Future so bright ... gotta wear shades : )

Future so bright ... gotta wear shades : )When you look at ROW, It's very early days. 
Our first true ROW drug - I'll take it.
The structure will eventually pay off in spades - IMO.

"With our 2022 revenue estimates currently forecasting approximately $288.6 million, the addition of Exelon represents a fully integrated revenue accretion of 27 per cent,” Novak wrote."

So, we still have a hundred million in the bank and that will likely have to do us for now.

Remember ... there's still $40M outstanding with CRA/QRA and that could go either way.  Would love to put that cash back in the bank.

Eventually the fund investments slowly trickle back too.

So ... the creation of a well oiled machine where cashflow is self-funding growth initiatives doesn't seem all that far away.  Also, we have the ongoing pursuit of small pharma partners to create the mega licensing deals of the future - but that will be more defined say 10-15 years from now.

Then ... we still have the shelf prospectus as a back-up for some big "gotta have" opportunities (maybe in Mexico).  Surely, Goodman could also utilize debt in the short-term and convert the debt in a future prospectus at a better share price.  There are options (IMO).

https://www.cantechletter.com/2021/04/gud-times-knight-therapeutics-wins-target-raise-at-raymond-james/



<< Previous
Bullboard Posts
Next >>